Table 1.
Details of the guidelines considered for evaluation.
| Organization | Year* | Total |
|---|---|---|
| ADA guideline | 2002-2021 | 20 |
| ADA EASD consensus statement | 2006, 2009 | 2 |
| ADA EASD position statement | 2012, 2019 | 2 |
| AACE guidelines | 2007, 2011 | 2 |
| AACE/ACE consensus statement | 2009, 2015-2018, 2020 | 6 |
| Malaysian clinical practice guideline | 2009, 2015, 2020 | 3 |
| NICE guidelines | 2008, 2009, 2015, 2019, 2020 | 5 |
| SEMDSA guidelines | 2009, 2012, 2017 | 3 |
| WHO guidelines | 2004, 2006, 2018, 2020 | 4 |
| IDF guidelines | 2011-2013, 2017 | 4 |
| RSSDI | 2017, 2019 | 2 |
| RSSDI-ESI clinical practice guidelines | 2020 | 1 |
| Diabetes Canada | 2018, 2020 | 2 |
| RACGP guidelines | 2011, 2012, 2014, 2016-2018, 2020 | 4 |
| GRAND TOTAL | - | 60 |
Note: *Includes guidelines that were available online.
Abbreviations: ADA: American Diabetes Association; AACE: American Association of Clinical Endocrinology; ACE: American College of Endocrinology; EASD: European Association for the Study of Diabetes; ESI: Endocrine Society of India; IDF: International Diabetes Federation; NICE: National Institute for Health and Care Excellence; RACGP: Royal Australian College of General Practitioners; RSSDI: Research Society for the Study of Diabetes in India; SEMDSA: Society for Endocrinology, Metabolism, and Diabetes of South Africa; WHO: World Health Organization.